Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVO: Adoptive Cellular Therapy in DIPG
NCT03396575Phase 1Terminated
- Sponsor
- University of Florida
- Start
- Jul 2018
- Primary completion
- Mar 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of TTRNA-xALT and TTRNA-DC vaccine in diffuse intrinsic pontine glioma (DIPG) and brainstem glioma (2 arms), sponsored by University of Florida. Primary endpoints: Feasibility and safety of adoptive cellular therapy and Maximally Achievable Dose or Maximum Tolerated Dose. Started Jul 2018; status: terminated.
02
Drugs
TTRNA-xALTTTRNA-DC vaccine
03
Conditions
diffuse intrinsic pontine glioma (DIPG)brainstem glioma
Beyond the preview
Go deeper on NCT03396575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396575.